Assess 123-I IMPY and SPECT Imaging as a Tool to Detect β-Amyloid in the Brain
Alzheimer Disease
About this trial
This is an interventional diagnostic trial for Alzheimer Disease focused on measuring Alzheimer, Alzheimer disease, Alzheimer disease (AD)
Eligibility Criteria
Inclusion Criteria: The participant is 50 years or older. Written informed consent is obtained. Participants have a clinical diagnosis of Alzheimer's disease based on National Institute of Neurological and Communicative Disorders and Stroke/Alzheimer's Disease and Related Disorders Association (NINCDS/ADRA) criteria. Mini-Mental Status Exam score > 16 and < 25. Patients have a diagnosis of probable AD for < 3 years prior to screening. Exclusion Criteria: The subject has signs or symptoms of another neurodegenerative disease including Parkinson's disease, diffuse Lewy body dementia, or history of significant cerebrovascular disease. Subjects with an iodine allergy. The subject has a clinically significant clinical laboratory value and/or medical or psychiatric illness. The subject has any disorder that may interfere with drug absorption distribution, metabolism, or excretion (including gastrointestinal surgery). The subject has evidence of clinically significant thyroid disease, gastrointestinal, cardiovascular, hepatic, renal, hematologic, neoplastic, endocrine, neurologic, immunodeficiency, pulmonary, or other medical or psychiatric disorder. The subject has received an investigational drug within 60 days before the screening visit. Pregnancy
Sites / Locations
- Institute for Neurodegenerative Disorders
Arms of the Study
Arm 1
Experimental
Assess [123I] IMPY & SPECT Imaging
To assess [123I] IMPY & SPECT Imaging